Ian Schowe

Mr. Ian Schowe

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2025 in Biology
Verified
Journal Article
Open access
PDF file
KBKurtis Breger
Kurtis Breger
ISIan Schowe
Ian Schowe
NSNoah A. Springer
Noah A. Springer
NONathan O'Leary
Nathan O'Leary
ARAgnieszka Ruszkowska
Agnieszka Ruszkowska
JBJessica Brown
Jessica Brown
Human methyltransferase-like protein 16 (METTL16) installs N6-methyladenosine on U6 small nuclear RNA (snRNA) and other RNAs. Multiple X-ray crystal structures of METTL16 have been published; however, we do not yet fully understand the structure–function relationships of specific residues. We designed 38 mutants, including seven cancer-associated mutants, and used electrophoretic mobility shift assays and single-turnover kinetic assays to better understand the functional roles of specific domains and amino acid residues in binding to U6 snRNA, formation of the METTL16•U6 snRNA•S-adenosylmethionine (SAM) complex, and the rate of methylation. While point mutations in the methyltransferase domain mildly weaken the binding of METTL16 to U6 snRNA, the C-terminal vertebrate conserved regions (VCRs), particularly the arginine-rich region (R382 to R388), mediate cooperative binding and contribute more to RNA binding. All METTL16 K-loop mutants displayed tighter SAM binding, suggesting that the K-loop blocks SAM binding. In addition, residues E133 and F227 are critical for stabilizing SAM binding. Mutations in the 184NPPF187 catalytic core and R282A abolished methyltransferase activity. Two METTL16 somatic cancer-associated mutants (G110C and R241Dfs*2) displayed reduced methylation activity. This mutational analysis expands our understanding of how specific domains and residues contribute to substrate-binding activity and methylation of U6 snRNA catalyzed by METTL16.

8 July 2025 in Nucleic Acids Research
Verified
Journal Article
Closed access
AKAlan C Kessler
Alan C Kessler
SMSandy Mattijssen
Sandy Mattijssen
GMGennady H Margolin
Gennady H Margolin
JPJack Prochnau
Jack Prochnau
JIJames R Iben
James R Iben
Richard MaraiaRichard Maraia
Richard Maraia
RNA polymerase III (Pol III) and some of its small non-coding RNAs have been co-opted by the immune system. We discovered a non-canonical activity for a human tRNA gene, TRT-TGT4-1, robust activation of interferon-stimulated gene (ISG) response after transfection into HEK293T cells, dependent on Pol III promoter-directed transcription and its flanking sequences. The activity requires the pattern recognition receptor RIG-I, which is activated by short RNAs with 5′-triphosphate (5′ppp). We characterized sequence-specific features of the TRT-TGT4-1 Pol III minimal T(4) terminator element which is uniquely required for and controls its ISG activity. Related, La protein, the Pol III transcript U(n)-3′ terminus-binding protein, can promote and/or suppress the activity. Screening identified other tRNA genes with ISG activity whose subsequent analysis revealed the ISG-positive and ISG-negative ones differ most significantly in the 5′-dinucleotides preceding their terminators and T(n) length. Replacing the ISG-positive consensus 5′AC of TRT-TGT4-1 with an ISG-negative terminator 5′GG, markedly decreased termination and ISG activity. The data support a model in which Pol III terminators can channel transcripts and affect their potential for ISG activity or tRNA maturation. The findings reveal insight into other tRNA gene features involved in ISG signaling, and suggest some tRNA genes may express such potential.